Literature DB >> 29055626

Pulmonary Arterial Hypertension With Abnormal V/Q Single-Photon Emission Computed Tomography.

Kenneth Chan1, Stefanos Ioannidis2, John G Coghlan2, Margaret Hall2, Benjamin E Schreiber3.   

Abstract

OBJECTIVES: This study aimed to evaluate the incidence and clinical outcomes of abnormal ventilation/perfusion (V/Q) single-photon emission computed tomography (SPECT) without thromboembolism, especially in patients with group I pulmonary arterial hypertension (PAH).
BACKGROUND: American Heart Association/American College of Cardiology and European Society of Cardiology guidelines recommend V/Q scan for screening for chronic thromboembolic pulmonary hypertension. The significance of patients with abnormal V/Q SPECT findings but no thromboembolism demonstrated in further investigations remained unclear. A distinct pattern of global patchy changes not typical of thromboembolism is recognized, but guidelines for reporting these in the context of PAH are lacking.
METHODS: A total of 136 patients who underwent V/Q SPECT and right-sided heart catheterization showing mean pulmonary arterial pressure ≥25 mm Hg were included. V/Q SPECT findings were reported using European Association of Nuclear Medicine criteria for pulmonary embolism followed by computed tomography pulmonary angiography screening for positive thromboembolism and further invasive pulmonary angiography for distal thromboembolism. The abnormal V/Q SPECT images were further analyzed according to perfusion pattern into focal or global perfusion defects.
RESULTS: V/Q SPECT showed thromboembolic disease in 44 patients, but 19 of these patients had no thromboembolism demonstrated by pulmonary angiography. Among these patients, 15 of 19 (78.9%) had group I PAH, and the majority had diffuse, patchy perfusion defects. After redefining V/Q SPECT images according to the perfusion pattern, those patients with global perfusion defects had higher mean pulmonary arterial pressure compared with patients with focal perfusion defects and normal scans (mean difference +13.9 and +6.2 mm Hg, respectively; p = 0.0002), as well as higher pulmonary vascular resistance (mean difference +316.6 and +226.3 absolute resistance units, respectively; p = 0.004). Among patients with PAH, global perfusion defects were associated with higher all-cause mortality with a hazard ratio of 5.63 (95% confidence interval: 1.11 to 28.5) compared with patients with focal or no perfusion abnormalities.
CONCLUSIONS: There is a high incidence of abnormal V/Q SPECT scans in nonthromboembolic PAH. Further studies are needed to investigate the poor outcome associated with abnormal V/Q SPECT findings in the context of PAH.
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic thromboembolic pulmonary hypertension; pulmonary angiogram; pulmonary arterial hypertension; pulmonary hypertension

Mesh:

Year:  2017        PMID: 29055626     DOI: 10.1016/j.jcmg.2017.07.026

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  3 in total

1.  Update in Pulmonary Vascular Disease 2016 and 2017.

Authors:  Evan L Brittain; Thennapan Thennapan; Bradley A Maron; Stephen Y Chan; Eric D Austin; Edda Spiekerkoetter; Harm J Bogaard; Christophe Guignabert; Roxane Paulin; Roberto F Machado; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 21.405

2.  Atypical bilateral ventilation/perfusion mismatches in an asymptomatic patient suffering from metastatic thyroid cancer.

Authors:  David Kersting; Christoph Rischpler; Till Plönes; Clemens Aigner; Lale Umutlu; Ken Herrmann; Hubertus Hautzel
Journal:  Eur J Hybrid Imaging       Date:  2021-12-20

Review 3.  Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19.

Authors:  Ranju T Dhawan; Deepa Gopalan; Luke Howard; Angelito Vicente; Mirae Park; Kavina Manalan; Ingrid Wallner; Peter Marsden; Surendra Dave; Howard Branley; Georgina Russell; Nishanth Dharmarajah; Onn M Kon
Journal:  Lancet Respir Med       Date:  2020-11-17       Impact factor: 30.700

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.